News - Page 79 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article First Patient Dosed in Small Pharma’s Drug Interaction Study

First Patient Dosed in Small Pharma’s Drug Interaction Study

Post published:December 15, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Ltd. Expands Life Offering to Quebec

Revive Therapeutics Ltd. Expands Life Offering to Quebec

Post published:December 15, 2022
Post category:Press Release

Read more about the article Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Post published:December 15, 2022
Post category:Press Release

Read more about the article FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

Post published:December 15, 2022
Post category:Press Release

Read more about the article Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Post published:December 14, 2022
Post category:Press Release

Read more about the article Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Post published:December 13, 2022
Post category:Press Release

Read more about the article Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects

Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects

Post published:December 12, 2022
Post category:Press Release

Read more about the article Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

Post published:December 12, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS

Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS

Post published:December 12, 2022
Post category:Psychedelic Bulletin

Read more about the article MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:December 9, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.